Integrated approach for the preoperative correction of anemia for liver resection in patients with colorectal liver metastases

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


Aim. To study the features of the pathogenesis of anemia in patients with colorectal cancer and metastatic liver damage, as well as to evaluate the effectiveness of etiological correction of anemia in the preoperative period.

Methods. 90 patients with colorectal liver metastases and anemia (hemoglobin content 75–95 g/L), who were observed at the City Clinical Oncological Center of St. Petersburg between 2014 and 2020, were included. The patients were divided into two groups. The first group consisted of prospectively assessed patients with the preoperative correction of anemia by iron supplements (intravenously 7 mg/kg once a week) and recombinant erythropoietin (subcutaneously 150 IU/kg 3 times a week). The second group included retrospectively assessed patients with the correction of anemia only by red blood cell (RBC) transfusion (1–3 doses). The groups were comparable for gender [sex ratio (male/female) was 17:31 and 16:26 for the first and the second groups, respectively; p >0.5], age (63.3±1.4 and 60.2±1.2 years, respectively; p >0.1) and hemoglobin content (87.4±1.0 and 86.7±0.9 g/l, respectively; p >0.2).

Results. In studying the causes of anemia, a decrease in the mean serum endogenous erythropoietin level was revealed in most patients (36.7±1.9 mIU/ml with the required 70 mIU/ml). A decrease in the concentration of serum iron (6.6±0.3 versus 15.1±0.8 μmol/l) and ferritin (15.5±1.9 versus 102.4±8.4 μg/ml) levels were revealed. At the same time, there was no difference in the concentration of pro-inflammatory cytokines in patients with anemia and healthy controls (tumor necrosis factor α, interleukin-1β, interleukin-6; p >0.2), which indicates a low activity of the immune system in response to a tumor, due to conducted chemotherapy. In the preoperative correction of anemia, a positive effect was achieved with both iron supplementation with erythropoietin preparation (the hemoglobin level increased from 87.6±1.0 to 108.1±0.9 g/l; p <0.01) and RBC transfusion (from 86.7±0.9 to 114.6±0.6 g/l; p <0.01).

Conclusion. In patients with colorectal liver metastases, the most common causes of anemia were low levels of erythropoietin and iron deficiency; also for this group of patients, the prescription of erythropoietin and intravenous iron preparations are effective for the preoperative correction of anemia.


Full Text

Restricted Access

About the authors

A E Alborov

Russian Research Institute of Hematology and Transfusiology; City Clinical Oncological Center

Author for correspondence.
Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia; Saint-Petersburg, Russia

M D Hanevich

Russian Research Institute of Hematology and Transfusiology; City Clinical Oncological Center

Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia; Saint-Petersburg, Russia

S S Bessmeltsev

Russian Research Institute of Hematology and Transfusiology

Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia

O E Rozanova

Russian Research Institute of Hematology and Transfusiology

Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia

T V Glazanova

Russian Research Institute of Hematology and Transfusiology

Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia

N A Romanenko

Russian Research Institute of Hematology and Transfusiology

Email: albor3331990@mail.ru

Russian Federation, Saint-Petersburg, Russia

References

  1. Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and CIS countries in 2009. Vestnik RONTs im. N.N. Blokhina RAMN. 2011; 22 (3, ­suppl. 1): 85. (In Russ.)
  2. Patyutko Yu.I., Sagaidak I.V., Polyakov A.N. et al. Surgery and chemotherapy plus surgery for patients with colorectal cancer liver metastases. Tazovaya khirurgiya i onkologiya. 2011; (1): 32–40. (In Russ.) doi: 10.24412/Fhr0i8_-Ots.
  3. Sekacheva M.I., Po­lishchuk L.O., Bagmet N.N., Skipenko O.G. Results of surgical treatment of metastatic colorectal cancer after drug therapy with bevacizumab. Journal of modern oncology. 2012; 14 (2): 38–41.(In Russ.)
  4. Zorina E.Yu., Orlova R.V. Prognostic factors of tumoral process in patients with disseminated colorectal cancer. Tazovaya khi­rurgiya i onkologiya. 2014; (2): 33–40. (In Russ.) doi: 10.17650/2220-3478-2014-0-2-33-40.
  5. Falcone A., Ricci S., Brunetti I. et al. Phase III ­trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J. Clin. Oncol. 2007; 25: 1670–1676. doi: 10.1200/JCO.2006.09.0928.
  6. Klinger M., Tamandl D., Eipeldauer S. et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann. Surg. Oncol. 2010; 17: 2059–2065. doi: 10.1245/s10434-010-0972-9.
  7. Tournigand C., Cervantes A., Figer A. et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced co­lorectal cancer — a GERCOR study. J. Clin. Oncol. 2006; 24: 394–400. doi: 10.1200/JCO.2005.03.0106.
  8. Ychou M., Hohenberger W., Thezenas S. et al. A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol. 2009; 20: 1964–1970. doi: 10.1093/annonc/mdp236.
  9. Ychou M., Viret F., Kramar A. et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemoth. Pharmacol. 2008; 62: 195–201. doi: 10.1310/hpj4607-482.
  10. Bessmeltsev S.S., Romanenko N.A. Anemiya pri opukholevykh zabolevaniyakh sistemy krovi. Rukovodstvo dlya vrachey. (Anemia in tumor diseases of the blood system. Hands. for doctors.) Moscow: SIMK. 2017; 228 p. (In Russ.)
  11. Glazanova T., Rozanova O., Romanenko N. Influence of inflammatory cytokines on genesis of anemia in lymphoproliferative disorder’s patients. In: Hemasphere. The abstract book of the 23th Congress of the European Hematology Association (EHA-23). 2018; 2 (s1): 896.
  12. Romanenko N.A., Bessmeltsev S.S., Albo­rov A.E. et al. Aspects of the pathogenesis of anemia in cancer patients. Kazan medical journal. 2019; 100 (6): 950–957. (In Russ.) doi: 10.17816/KMJ2019-950.
  13. Protokoly klinicheskikh rekomendatsiy podderzhiva­yushchey terapii v onkologii. (Protocols of clinical recommendations for supportive therapy in Oncology.) Ed. by M.I. Davydov. 2nd edition, revised and enlarged. Moscow. 2018; 228 p. www.rassc.org (access date: 17.04.2020). (In Russ.)

Supplementary files

Supplementary Files Action
1.
Рис. 1. Сравнение концентраций провоспалительных цитокинов у пациентов с метастатическим поражением печени с анемией и здоровых доноров (контроль); ФНО — фактор некроза опухоли; ИЛ — интерлейкин

Download (19KB) Indexing metadata
2.
Рис. 2. Динамика содержания гемоглобина на фоне коррекции анемии

Download (18KB) Indexing metadata

Statistics

Views

Abstract - 45

PDF (Russian) - 1

Cited-By


Article Metrics

Metrics Loading ...

PlumX

Dimensions


© 2020 Alborov A.E., Hanevich M.D., Bessmeltsev S.S., Rozanova O.E., Glazanova T.V., Romanenko N.A.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies